Elanco Animal Health (NYSE:ELAN) Now Covered by Barclays

Barclays began coverage on shares of Elanco Animal Health (NYSE:ELAN) in a research report sent to investors on Tuesday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $30.00 price target on the stock.

A number of other research analysts have also weighed in on the company. Zacks Research lowered Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. UBS Group raised their price target on Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Piper Sandler lifted their price objective on Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, August 11th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday, December 1st. Finally, KeyCorp started coverage on shares of Elanco Animal Health in a report on Friday, November 21st. They issued an “overweight” rating and a $27.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.78.

Elanco Animal Health Trading Down 5.7%

ELAN stock opened at $20.45 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. Elanco Animal Health has a 1-year low of $8.02 and a 1-year high of $23.70. The business has a 50 day simple moving average of $21.69 and a two-hundred day simple moving average of $17.93. The company has a market capitalization of $10.16 billion, a price-to-earnings ratio of 340.96, a PEG ratio of 2.94 and a beta of 1.86.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the previous year, the firm earned $0.13 earnings per share. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Research analysts anticipate that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Several institutional investors have recently made changes to their positions in ELAN. SJS Investment Consulting Inc. grew its holdings in Elanco Animal Health by 2,563.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after purchasing an additional 1,333 shares during the last quarter. Huntington National Bank boosted its position in shares of Elanco Animal Health by 136.7% during the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after buying an additional 1,087 shares during the period. Whittier Trust Co. of Nevada Inc. boosted its position in shares of Elanco Animal Health by 80.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after buying an additional 900 shares during the period. Farther Finance Advisors LLC grew its stake in shares of Elanco Animal Health by 79.3% during the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock valued at $43,000 after buying an additional 951 shares during the last quarter. Finally, First Horizon Advisors Inc. raised its holdings in shares of Elanco Animal Health by 184.3% in the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock worth $53,000 after buying an additional 2,414 shares during the period. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.